Cellectis is a global clinical-stage biopharmaceutical company focused on developing pioneering treatments to address unmet medical needs. Established in 1999, the company has leveraged its 26 years of expertise in genome editing, especially in the fields of immuno-oncology and gene therapy. Its mission is underscored by the slogan, "Cellectis is developing life-changing product candidates to target and eradicate cancer cells."
Notably, Cellectis has developed allogeneic CAR-T cells using proprietary gene-editing technology. Its primary clinical programs are targeting B-cell acute lymphoblastic leukemia (B-ALL) and non-Hodgkin lymphoma (NHL). With full vertical integration from Paris for production of starting materials to Raleigh, NC for manufacturing finished products, Cellectis ensures uncompromised quality across its operations.
Strategic collaborations with industry leaders like AstraZeneca and Allogene Therapeutics further bolster its research in oncology and rare diseases. Headquartered in Paris, with additional offices in New York and Raleigh, the company is publicly traded on both the Nasdaq Global Market and Euronext Growth under the tickers CLLS and ALCLS, respectively.